By teaming with Bayer to develop in vitro diagnostics for HIV drug resistance, Amersham Biosciences is hoping to take aim at one-time rival Applied Biosystems in a large and steadily growing market.
The move will also pit Bayer, the No. 3 diagnostic manufacturer, against Abbott Labs, the No. 2 shop, in a largest corner corner of the $50 million HIV-resistance space.
Trouble for Amersham and Bayer is that ABI and corporate kin Celera Diagnostics already have a trio of platforms approved for this indication. Are Bayer and Amersham too far behind?